Sports Medicine

, Volume 34, Issue 8, pp 513–554 | Cite as

Effects of Androgenic-Anabolic Steroids in Athletes

  • Fred HartgensEmail author
  • Harm Kuipers
Review Article


Androgenic-anabolic steroids (AAS) are synthetic derivatives of the male hormone testosterone. They can exert strong effects on the human body that may be beneficial for athletic performance. A review of the literature revealed that most laboratory studies did not investigate the actual doses of AAS currently abused in the field. Therefore, those studies may not reflect the actual (adverse) effects of steroids. The available scientific literature describes that short-term administration of these drugs by athletes can increase strength and bodyweight. Strength gains of about 5–20% of the initial strength and increments of 2–5kg bodyweight, that may be attributed to an increase of the lean body mass, have been observed. A reduction of fat mass does not seem to occur. Although AAS administration may affect erythropoiesis and blood haemoglobin concentrations, no effect on endurance performance was observed. Little data about the effects of AAS on metabolic responses during exercise training and recovery are available and, therefore, do not allow firm conclusions.

The main untoward effects of short- and long-term AAS abuse that male athletes most often self-report are an increase in sexual drive, the occurrence of acne vulgaris, increased body hair and increment of aggressive behaviour. AAS administration will disturb the regular endogenous production of testosterone and gonadotrophins that may persist for months after drug withdrawal. Cardiovascular risk factors may undergo deleterious alterations, including elevation of blood pressure and depression of serum high-density lipoprotein (HDL)-, HDL2- and HDL3-cholesterol levels. In echocardiographic studies in male athletes, AAS did not seem to affect cardiac structure and function, although in animal studies these drugs have been observed to exert hazardous effects on heart structure and function. In studies of athletes, AAS were not found to damage the liver. Psyche and behaviour seem to be strongly affected by AAS. Generally, AAS seem to induce increments of aggression and hostility. Mood disturbances (e.g. depression, [hypo-]mania, psychotic features) are likely to be dose and drug dependent. AAS dependence or withdrawal effects (such as depression) seem to occur only in a small number of AAS users. Dissatisfaction with the body and low self-esteem may lead to the so-called ‘reverse anorexia syndrome’ that predisposes to the start of AAS use. Many other adverse effects have been associated with AAS misuse, including disturbance of endocrine and immune function, alterations of sebaceous system and skin, changes of haemostatic system and urogenital tract. One has to keep in mind that the scientific data may underestimate the actual untoward effects because of the relatively low doses administered in those studies, since they do not approximate doses used by illicit steroid users.

The mechanism of action of AAS may differ between compounds because of variations in the steroid molecule and affinity to androgen receptors. Several pathways of action have been recognised. The enzyme 5-α-reductase seems to play an important role by converting AAS into dihydrotestosterone (androstanolone) that acts in the cell nucleus of target organs, such as male accessory glands, skin and prostate. Other mechanisms comprises mediation by the enzyme aromatase that converts AAS in female sex hormones (estradiol and estrone), antagonistic action to estrogens and a competitive antagonism to the glucocorticoid receptors. Furthermore, AAS stimulate erythropoietin synthesis and red cell production as well as bone formation but counteract bone breakdown. The effects on the cardiovascular system are proposed to be mediated by the occurrence of AAS-induced atherosclerosis (due to unfavourable influence on serum lipids and lipoproteins), thrombosis, vasospasm or direct injury to vessel walls, or may be ascribed to a combination of the different mechanisms. AAS-induced increment of muscle tissue can be attributed to hypertrophy and the formation of new muscle fibres, in which key roles are played by satellite cell number and ultrastructure, androgen receptors and myonuclei.


Testosterone Androgen Receptor Satellite Cell Lean Body Mass Serum Total Cholesterol Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Preparation of this manuscript was financially supported by a grant from the Netherlands Centre for Doping Affairs, Capelle aan den IJssel, The Netherlands. The authors did not receive any (financial) support or other benefits from a commercial entity, nor any agreement to provide such benefits from a commercial entity. The authors do not have a relationship with any company or manufacturer of any commercial product mentioned in this manuscript or with companies or manufacturers that might benefit from this manuscript.


  1. 1.
    Todd T. Anabolic steroids: the gremlins of sport. J Sport Hist 1987; 14: 87–107PubMedGoogle Scholar
  2. 2.
    Wade N. Anabolic steroids: doctors denounce them, but athletes aren’t listening. Science 1972; 176: 1399–403PubMedGoogle Scholar
  3. 3.
    Yesalis CE, Courson SP, Wright JE. History of anabolic steroid use in sport and exercise. In: Yesalis C, editor. Anabolic steroids in sports and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 51–72Google Scholar
  4. 4.
    International Olympic Committee. Statistics 1997 of the IOC accredited laboratories. Lausanne: International Olympic Committee, 1998Google Scholar
  5. 5.
    Alén M, Rahkila P. Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes. Sports Med 1988; 6: 327–32PubMedGoogle Scholar
  6. 6.
    Bahrke MS, Yesalis CR, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids: an update. Sports Med 1996; 22: 367–90PubMedGoogle Scholar
  7. 7.
    Friedl KE. Effects of anabolic steroids on physical health. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 175–224Google Scholar
  8. 8.
    Huie MJ. An acute myocardial infarction occurring in an anabolic steroid user (case study). Med Sci Sports Exerc 1994; 26: 408–13PubMedGoogle Scholar
  9. 9.
    Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987; 7: 230–6PubMedGoogle Scholar
  10. 10.
    Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995; 27: 1252–62PubMedGoogle Scholar
  11. 11.
    Pope HG, Katz DL. Psychiatric effects of anabolic steroids. Psychiatr Ann 1992; 22: 24–9Google Scholar
  12. 12.
    Rockhold RW. Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 1993; 33: 497–520PubMedGoogle Scholar
  13. 13.
    Wilson JD. Androgen abuse by athletes. Endocr Rev 1988; 9: 181–99PubMedGoogle Scholar
  14. 14.
    Kochakian CD. Anabolic-androgenic steroids. Berlin: Springer Verlag, 1976Google Scholar
  15. 15.
    Kochakian CD. History, chemistry and pharmacodynamics of anabolic-androgenic steroids. Wien Med Wochenschr 1993; 143: 359–63PubMedGoogle Scholar
  16. 16.
    Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol Suppl Copenh 1985; 271: 11–8PubMedGoogle Scholar
  17. 17.
    Wilson J. Androgens. In: Hardman J, Limbird L, editors. Goodman and Gilman’s the pharmacological basis of therapeurics. 9th ed. New York: McGraw-Hill, 1996: 1441–57Google Scholar
  18. 18.
    Bartsch W. Anabolic steroids: action on cellular level. In: Kopera H, editor. Anabolic-androgenic steroids towards the year 2000. Vienna: Blackwell-MZV, 1993: 29–39Google Scholar
  19. 19.
    Anderson RA, Wallace AM, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study, III: higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 1996; 81: 902–8PubMedGoogle Scholar
  20. 20.
    Nieschlag E, Behre HM. Testosterone: action-deficiency-substitution. Berlin: Springer Verlag, 1990Google Scholar
  21. 21.
    Wu F. Male contraception. Baillieres Clin Obstet Gynaecol 1996; 10: 1–23PubMedGoogle Scholar
  22. 22.
    Wu FW. Treatment of infertility: infertility in men. Prescr J 1996; 36: 55–61Google Scholar
  23. 23.
    Creutzberg EC, Schols AM. Anabolic steroids. Curr Opin Clin Nutr Metab Care 1999; 2: 243–53PubMedGoogle Scholar
  24. 24.
    Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19–28PubMedGoogle Scholar
  25. 25.
    Schols A, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268–74PubMedGoogle Scholar
  26. 26.
    Berger JR, Pall L, Winfield D. Effect of anabolic steroids on HIV-related wasting myopathy. South Med J 1993; 86: 865–6PubMedGoogle Scholar
  27. 27.
    Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10: 745–52PubMedGoogle Scholar
  28. 28.
    Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 137–46PubMedGoogle Scholar
  29. 29.
    Strawford A, Barbieri T, Van LM, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA 1999; 281: 1282–90PubMedGoogle Scholar
  30. 30.
    Welle S, Jozefowicz R, Forbes G, et al. Effect of testosterone on metabolic rate and body composition in normal men and men with muscular dystrophy. J Clin Endocrinol Metab 1992; 74: 332–5PubMedGoogle Scholar
  31. 31.
    Fox RW. Update on urticaria and angioedema (hives). Allergy Proc 1995; 16: 289–92PubMedGoogle Scholar
  32. 32.
    Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995; 33: 254–8PubMedGoogle Scholar
  33. 33.
    Urhausen A, Holpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 1989; 58: 633–40Google Scholar
  34. 34.
    Sachtleben TR, Berg KE, Elias BA, et al. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 1993; 25: 1240–5PubMedGoogle Scholar
  35. 35.
    De Boer A, van Haren SF, Hartgens F, et al. Onderzoek naar het gebruik van prestatieverhogende middelen bij bodybuilders in Nederland. Utrecht: Centrum voor Dopingvraagstukken, Universiteit Utrecht, 1996Google Scholar
  36. 36.
    Alén M, Hakkinen K. Androgenic steroid effects on serum hormones and on maximal force development in strength athletes. J Sports Med Phys Fitness 1987; 27: 38–46PubMedGoogle Scholar
  37. 37.
    Alén M, Hakkinen K, Komi PV. Changes in neuromuscular performance and muscle fiber characteristics of elite power athletes self-administering androgenic and anabolic steroids. Acta Physiol Scand 1984; 122: 535–44PubMedGoogle Scholar
  38. 38.
    Ariel G. The effect of anabolic steroid upon skeletal muscle contractile force. J Sports Med Phys Fitness 1973; 13: 187–90PubMedGoogle Scholar
  39. 39.
    Ariel G. Prolonged effects of anabolic steroid upon muscular contractile force. Med Sci Sports 1974; 6: 62–4PubMedGoogle Scholar
  40. 40.
    Ariel G. Residual effect of an anabolic steroid upon isotonic muscular force. J Sports Med Phys Fitness 1974; 14: 103–11PubMedGoogle Scholar
  41. 41.
    Ariel G, Saville W. Anabolic steroids: the physiological effects of placebos. Med Sci Sports 1972; 4: 124–6Google Scholar
  42. 42.
    Bowers RW, Reardon JP. Effects of methandrostenolone (Dianabol) on strength development and aerobic capacity [abstract]. Med Sci Sports 1972; 4: 54Google Scholar
  43. 43.
    Crist DM, Stackpole PJ, Peake GT. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. J Appl Physiol 1983; 54: 366–70PubMedGoogle Scholar
  44. 44.
    Fahey TD, Brown CH. The effects of an anabolic steroid on the strength, body composition, endurance of college males when accompanied by a weight training program. Med Sci Sports 1973; 5: 272–6PubMedGoogle Scholar
  45. 45.
    Fowler WM, Gardner GW, Egstrom GH. Effect of an anabolic steroid on physical performance of young men. J Appl Physiol 1965; 20: 1038–40PubMedGoogle Scholar
  46. 46.
    Freed D, Banks AJ, Longson D. Anabolic steroids in athletics. BMJ 1972; 3: 761PubMedGoogle Scholar
  47. 47.
    Freed DL, Banks AJ. A double-blind crossover trial of methandienone (Dianabol, CIBA) in moderate dosage on highly trained experienced athletes. Br J Sports Med 1975; 9: 78–82PubMedGoogle Scholar
  48. 48.
    Freed DLJ, Banks AJ, Longson D, et al. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. BMJ 1975; 2: 471–3PubMedGoogle Scholar
  49. 49.
    Friedl KE, Dettori JR, Hannan CJ, et al. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J Steroid Biochem Mol Biol 1991; 40: 607–12PubMedGoogle Scholar
  50. 50.
    Golding LA, Freydinger JE, Fishel SS. Weight, size and strength: unchanged with steroids. Phys Sportsmed 1974; 2: 39–43Google Scholar
  51. 51.
    Hartgens F, Van Marken Lichtenbelt W, Ebbing S, et al. Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. Int J Sports Med 2001; 22: 235–41PubMedGoogle Scholar
  52. 52.
    Hartgens F, Van Marken Lichtenbelt W, Ebbing S, et al. Androgenic-anabolic steroids induced body changes in strength athletes. Phys Sportsmed 2001; 29: 49–66PubMedGoogle Scholar
  53. 53.
    Hervey GR, Hutchinson I, Knibbs AV, et al. ‘Anabolic’ effects of methandienone in men undergoing athletic training. Lancet 1976; II: 699–702Google Scholar
  54. 54.
    Hervey GR, Knibbs AV, Burkinshaw L, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci 1981; 60: 457–61PubMedGoogle Scholar
  55. 55.
    Johnson LC, Fisher G, Silvester LJ, et al. Anabolic steroid: effects on strength, body weight, oxygen uptake and spermatogenesis upon mature males. Med Sci Sports 1972; 4: 43–5PubMedGoogle Scholar
  56. 56.
    Johnson LC, O’Shea JP. Anabolic steroid: effects on strength development. Science 1969; 164: 957–9PubMedGoogle Scholar
  57. 57.
    Johnson LC, Roundy ES, Allsen PE, et al. Effect of anabolic steroid treatment on endurance. Med Sci Sports 1975; 7: 287–9PubMedGoogle Scholar
  58. 58.
    Keul J, Deus B, Kindermann W. Anabole hormone: Schädigung, Leistungsfähigkeit und Stoffwechsel. Med Klin 1976; 71: 497–503PubMedGoogle Scholar
  59. 59.
    Kuipers H, Wijnen JAG, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver function in bodybuilders. Int J Sports Med 1991; 12: 413–8PubMedGoogle Scholar
  60. 60.
    Loughton SJ, Ruhling RO. Human strength and endurance responses to anabolic steroid and training. J Sports Med Phys Fitness 1977; 17: 285–96PubMedGoogle Scholar
  61. 61.
    O’Shea JP. A biochemical evaluation of the effects of stanozolol on adrenal, liver and muscle function in humans. Nutr Rep Int 1974; 10: 381–8Google Scholar
  62. 62.
    O’Shea JP. The effects of an anabolic steroid on dynamic strength levels of weightlifters. Nutr Rep Int 1971; 4: 363–70Google Scholar
  63. 63.
    O’Shea JP, Winkler W. Biochemical and physical effects of an anabolic steroid in competitive swimmers and weightlifters. Nutr Rep Int 1970; 2: 351–62Google Scholar
  64. 64.
    Samuels LT, Henschel AF, Keys A. Influence of methyl testosterone on muscular work and creatine metabolism in normal young men. J Clin Endocr 1942; 2: 649–54Google Scholar
  65. 65.
    Stamford BA, Moffatt R. Anabolic steroid: effectiveness as an ergogenic aid to experienced weight trainers. J Sports Med Phys Fitness 1974; 14: 191–7PubMedGoogle Scholar
  66. 66.
    Steinbach M. Über den Einfluβ anaboler Wirkstoffe auf Körpergewicht, Muskelkraft und Muskeltraining. Sportartz Sportmedizin 1968; 19: 485–92Google Scholar
  67. 67.
    Strømme SB, Meen HD, Aakvaag A. Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males. Med Sci Sports 1974; 6: 203–8PubMedGoogle Scholar
  68. 68.
    Weiss U, Müller H. Zür Frage der beeinflüssung des Krafttrainings durch anabole Hormone. Schweiz Z Sportmed 1968; 16(2): 79–89PubMedGoogle Scholar
  69. 69.
    Win-May M, Mya-Tu M. The effect of anabolic steroids on physical fitness. J Sports Med Phys Fitness 1975; 15: 266–71PubMedGoogle Scholar
  70. 70.
    Casner SJ, Early RG, Carlson BR. Anabolic steroid effects on body composition in normal young men. J Sports Med Phys Fitness 1971; 11: 98–103PubMedGoogle Scholar
  71. 71.
    Ward P. The effect of an anabolic steroid on strength and lean body mass. Med Sci Sports 1973; 5: 277–82PubMedGoogle Scholar
  72. 72.
    Van Marken Lichtenbelt WD, Hartgens F, Ebbing S, et al. Body compostion changes in bodybuilders: a method comparison. Med Sci Sports Exerc 2004; 38(3): 490–7Google Scholar
  73. 73.
    Van Marken Lichtenbelt WD, Hartgens F, Ebbing S, et al. Bodybuilders’ body composition: effect of nandrolone decanoate. Med Sci Sports Exerc 2004; 38(3): 484–9Google Scholar
  74. 74.
    Kilshaw BH, Harkness RA, Hobson BM, et al. The effects of large doses of the anabolic steroid, methandrostenolone, on an athlete. Clin Endocrinol Oxf 1975; 4: 537–41PubMedGoogle Scholar
  75. 75.
    Alén M, Hakkinen K, Komi PV. Changes in muscle power production capacity in power athletes self-administering androgenic anabolic steroids. Duodecim 1984; 100: 1096–104PubMedGoogle Scholar
  76. 76.
    Forbes GB, Porta CR, Herr BE, et al. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA 1992; 267: 397–9PubMedGoogle Scholar
  77. 77.
    Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1–7PubMedGoogle Scholar
  78. 78.
    Giorgi A, Weatherby RP, Murphy PW. Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study. J Sci Med Sport 1999; 2: 341–55PubMedGoogle Scholar
  79. 79.
    Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172–81PubMedGoogle Scholar
  80. 80.
    Kouri EM, Pope HJ, Katz DL, et al. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sport Med 1995; 5: 223–8PubMedGoogle Scholar
  81. 81.
    Kadi F. Adaptation of human skeletal muscle to training and anabolic steroids. Acta Physiol Scand Suppl 2000; 646: 1–52PubMedGoogle Scholar
  82. 82.
    Kadi F, Bonnerud P, Eriksson A, et al. The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem Cell Biol 2000; 113: 25–9PubMedGoogle Scholar
  83. 83.
    Griggs RC, Kingston W, Jozefowicz RF, et al. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol 1989; 66: 498–503PubMedGoogle Scholar
  84. 84.
    Bhasin S. The dose-dependent effects of testosterone on sexual function and on muscle mass and function. Mayo Clin Proc 2000; 75 Suppl.: S70–5PubMedGoogle Scholar
  85. 85.
    Hartgens F, van Straaten H, Fideldij S, et al. Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. Eur J Appl Physiol 2002; 86: 233–9PubMedGoogle Scholar
  86. 86.
    Kadi F, Eriksson A, Holmner S, et al. Cellular adaptation of the trapezius muscle in strength-trained athletes. Histochem Cell Biol 1999; 111: 189–95PubMedGoogle Scholar
  87. 87.
    Kadi F, Eriksson A, Holmner S, et al. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Med Sci Sports Exerc 1999; 31: 1528–34PubMedGoogle Scholar
  88. 88.
    Kuipers H, Peeze BF, Hartgens F, et al. Muscle ultrastructure after strength training with placebo or anabolic steroid. Can J Appl Physiol 1993; 18: 189–96PubMedGoogle Scholar
  89. 89.
    Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002; 283: E154–64PubMedGoogle Scholar
  90. 90.
    Holma P. Effect of an anabolic steroid (metandienone) on central and peripheral blood flow in well-trained male athletes. Ann Clin Res 1977; 9: 215–21PubMedGoogle Scholar
  91. 91.
    Hartgens F, Kuipers H, Wijnen J, et al. Body composition, cardiovascular risk factors and liver function in long term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal. Int J Sports Med 1996; 17: 429–33PubMedGoogle Scholar
  92. 92.
    Sinha-Hikim I, Roth SM, Lee MI, et al. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab 2003; 285: E197–205PubMedGoogle Scholar
  93. 93.
    Rademacher G, Gedrat J, Häcker R, et al. Die Beeinflussung des Adaptationsverhalten ausgewählter Funktionssysteme von Ausdauersportlern während einer kraftbetohnten Training-sphase durch die zusätzliche Gabe von Oral-Turinabol®. In: Häcker R, Marées HD, editors. Hormonelle Regulation und psychophysische Belastung im Leistungssport. Köln: Deutscher Ärzte-Verlag, 1991: 77–84Google Scholar
  94. 94.
    Elashoff JD, Jacknow AD, Shain SG, et al. Effects of anabolicandrogenic steroids on muscular strength. Ann Intern Med 1991; 115: 387–93PubMedGoogle Scholar
  95. 95.
    Hinterberger W, Vierhapper H. Anabolic steroids and blood cell production. Wien Med Wochenschr 1993; 143: 380–2PubMedGoogle Scholar
  96. 96.
    Alén M. Androgenic steroid effects on liver and red cells. Br J Sports Med 1985; 19: 15–20PubMedGoogle Scholar
  97. 97.
    Hartgens F, Hamulyak K, Pernot C, et al. Effects of high doses androgenic-anabolic steroids on haematologic parameters in bodybuilders. Abstract from the 8th FIMS European Sports Medicine Congress; 1995 Oct 23–27; Granada, 80Google Scholar
  98. 98.
    Jakob E, Hoffman R, Fuchs F, et al. Testosteronapplikation und Leistungsfähigkeit bei Skilanglaufern. Deutsche Zeitschrift fur Sportmedizin 1988; 39: 41–5Google Scholar
  99. 99.
    Boone Jr JB, Lambert CP, Flynn MG, et al. Resistance exercise effects on plasma cortisol, testosterone and creatine kinase activity in anabolic-androgenic steroid users. Int J Sports Med 1990; 11: 293–7PubMedGoogle Scholar
  100. 100.
    McKillop G, Ballantyne FC, Borland W, et al. Acute metabolic effects of exercise in bodybuilders using anabolic steroids. Br J Sports Med 1989; 23: 186–7PubMedGoogle Scholar
  101. 101.
    McKillop G, Ballantyne FC, Borland W, et al. The short-term metabolic effects of strenuous exercise in bodybuilders. Br J Sports Med 1988; 22: 107–8PubMedGoogle Scholar
  102. 102.
    Rozenek R, Rahe CH, Kohl HH, et al. Physiological responses to resistance-exercise in athletes self-administering anabolic steroids. J Sports Med Phys Fitness 1990; 30: 354–60PubMedGoogle Scholar
  103. 103.
    Urhausen A, Stein R, Kindermann W. Metabolismus und hormonelles Verhalten bei Ausdauertrainierten unter Testosteronapplikation. Dtsch Z Sportmed 1989; 40: 312–20Google Scholar
  104. 104.
    Tamaki T, Uchiyama S, Uchiyama Y, et al. Anabolic steroids increase exercise tolerance. Am J Physiol Endocrinol Metab 2001; 280: E973–81PubMedGoogle Scholar
  105. 105.
    Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA 1985; 253: 2871–3PubMedGoogle Scholar
  106. 106.
    Strauss RH, Wright JE, Finerman GAM, et al. Side effects of anabolic steroids in weight trained men. Phys Sportsmed 1983; 11: 87–96Google Scholar
  107. 107.
    Tricker R, O’Neill MR, Cook D. The incidence of anabolic steroid use among competitive bodybuilders. J Drug Educ 1989; 19: 313–25PubMedGoogle Scholar
  108. 108.
    Yesalis CE, Herrick RT, Buckley RT, et al. Self-reported use of anabolic-androgenic steroids by elite power lifters. Phys Sportsmed 1988; 16: 90–100Google Scholar
  109. 109.
    Alén M, Reinila M, Vihko R. Response of serum hormones to androgen administration in power athletes. Med Sci Sports Exerc 1985; 17: 354–9PubMedGoogle Scholar
  110. 110.
    Clerico A, Ferdeghini M, Palombo C, et al. Effect of anabolic treatment on the serum levels of gonadotropins, testosterone, prolactin, thyroid hormones and myoglobin of male athletes under physical training. J Nucl Med Allied Sci 1981; 25: 79–88PubMedGoogle Scholar
  111. 111.
    Torres-Calleja J, Gonzalez-Unzaga M, DeCelis-Carrillo R, et al. Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. Life Sci 2001; 68: 1769–74PubMedGoogle Scholar
  112. 112.
    Anderson RA, Wu F. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study, II: pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 1996; 81: 896–901PubMedGoogle Scholar
  113. 113.
    Bijlsma JW, Duursma SA, Thijssen JH, et al. Influence of nandrolondecanoate on the pituitary-gonadal axis in males. Acta Endocrinol Copenh 1982; 101: 108–12PubMedGoogle Scholar
  114. 114.
    Alén M, Rahkila P, Reinila M, et al. Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. Am J Sports Med 1987; 15: 357–61PubMedGoogle Scholar
  115. 115.
    Mauss J, Börsch G, Bormacher K, et al. Effect of long-term testosterone oenanthate administration on male reproductive function: clinical evaluation, serum FSH, LH, testosterone, seminal fluid analyses in normal men. Acta Endocrinol 1975; 78: 373–84PubMedGoogle Scholar
  116. 116.
    Ruokonen A, Alen M, Bolton N, et al. Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man. J Steroid Biochem 1985; 23: 33–8PubMedGoogle Scholar
  117. 117.
    Matsumine H, Hirato K, Ynaihara T, et al. Aromatization by skeletal muscle. J Clin Endocrinol Metab 1986; 63: 717–20PubMedGoogle Scholar
  118. 118.
    Alén M, Suominen J. Effect of androgenic and anabolic steroids on spermatogenesis in power athletes. Int J Sports Med 1984; 5: 189–92Google Scholar
  119. 119.
    Schürmeyer T, Belkien L, Knuth UA, et al. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet 1984; I: 417–20Google Scholar
  120. 120.
    Martikainen H, Alen M, Rahkila P, et al. Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes. J Steroid Biochem 1986; 25: 109–12PubMedGoogle Scholar
  121. 121.
    Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 2003; 79: 203–5PubMedGoogle Scholar
  122. 122.
    Menon K. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotrophin an human menopausal gonadotropin. Fertil Steril 2003; 79Suppl. 3: 1659–61PubMedGoogle Scholar
  123. 123.
    Karila T, Hovatta O, Seppala T. Concomitant abuse of anabolic-androgenic steroids and human choronic gonadotrophin impairs spermatogenesis in power athletes. Int J Sports Med 2004; 25(4): 257–63PubMedGoogle Scholar
  124. 124.
    Neild D. Gynaecomastia in bodybuilders. Br J Clin Pract 1995; 49: 172PubMedGoogle Scholar
  125. 125.
    Spiga L, Gorrini G, Ferraris L, et al. Unilateral gynecomastia induced by the use of anabolic steroids: a clinical case report [in Italian]. Minerva Med 1992; 83: 575–80PubMedGoogle Scholar
  126. 126.
    Reyes RJ, Zicchi S, Hamed H, et al. Surgical correction of gynaecomastia in bodybuilders. Br J Clin Pract 1995; 49: 177–9PubMedGoogle Scholar
  127. 127.
    Friedl KE, Yesalis CE. Self-treatment of gynecomastia in bodybuilders who use anabolic steroids. Phys Sportsmed 1989; 17: 67–79Google Scholar
  128. 128.
    Dickerman RD, McConathy WJ, Schaller F, et al. Cardiovascular complications and anabolic steroids [letter]. Eur Heart J 1996; 17: 1912PubMedGoogle Scholar
  129. 129.
    Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J 1992; 124: 507–8PubMedGoogle Scholar
  130. 130.
    LaRosee K, Schulz A, Bohm M, et al. Kardiale Dekompensation eines Bodybuilders. Dtsch Med Wochenschr 1997; 122: 1586–90Google Scholar
  131. 131.
    McCarthy K, Tang AT, Dalrymple-Hay MJ, et al. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg 2000; 70: 658–60PubMedGoogle Scholar
  132. 132.
    McKillop G, Todd IC, Ballantyne D. Increased left ventricular mass in a bodybuilder using anabolic steroids. Br J Sports Med 1986; 20: 151–2PubMedGoogle Scholar
  133. 133.
    Mochizucki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Phys Sportsmed 1988; 16: 109–14Google Scholar
  134. 134.
    Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17: 1576–83PubMedGoogle Scholar
  135. 135.
    Stolt A, Karila T, Viitasalo M, et al. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999; 84: 364–6, A9PubMedGoogle Scholar
  136. 136.
    Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851–7PubMedGoogle Scholar
  137. 137.
    Dickerman RD, Schaller F, Prather I, et al. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 1995; 86: 172–3PubMedGoogle Scholar
  138. 138.
    Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses 1991; 35: 27–31PubMedGoogle Scholar
  139. 139.
    Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 2001; 125: 253–5PubMedGoogle Scholar
  140. 140.
    Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death: a case report and review of the literature. Int J Legal Med 1998; 111: 261–4PubMedGoogle Scholar
  141. 141.
    Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158: 346–8PubMedGoogle Scholar
  142. 142.
    Luke JL, Farb A, Virmani R, et al. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci 1990; 35: 1441–7PubMedGoogle Scholar
  143. 143.
    Friedl KE, Hannan CJ, Jones RE, et al. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69–74PubMedGoogle Scholar
  144. 144.
    Hartgens F, Cheriex E, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24: 344–51PubMedGoogle Scholar
  145. 145.
    Kleiner SM, Calabrese LH, Fiedler KM, et al. Dietary influences on cardiovascular disease risk in anabolic steroid-using and nonusing bodybuilders [published erratum appears in J Am Coll Nutr 1989 Aug; 8 (4): 357]. J Am Coll Nutr 1989; 8: 109–19PubMedGoogle Scholar
  146. 146.
    Thompson PD, Sadaniantz A, Cullinane EM, et al. Left ventricular function is not impaired in weight-lifters who use anabolic steroids. J Am Coll Cardiol 1992; 19: 278–82PubMedGoogle Scholar
  147. 147.
    Karila TA, Karjalainen JE, Mantysaari MJ, et al. Anabolicandrogenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 2003; 24(5): 337–43PubMedGoogle Scholar
  148. 148.
    Lenders JW, Demacker PN, Vos JA, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, liver function in amateur body builders. Int J Sports Med 1988; 9: 19–23PubMedGoogle Scholar
  149. 149.
    Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc 1992; 24: 633–7PubMedGoogle Scholar
  150. 150.
    Grace F, Sculpthorne N, Baker J, et al. Blood pressure and rate pressure response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport 2003; 6(3): 307–12PubMedGoogle Scholar
  151. 151.
    Alén M, Rahkila P. Reduced high-density lipoprotein-cholesterol in power athletes: use of male sex hormone derivates, an atherogenic factor. Int J Sports Med 1984; 5: 341–2PubMedGoogle Scholar
  152. 152.
    Alén M, Rahkila P, Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int J Sports Med 1985; 6: 139–44PubMedGoogle Scholar
  153. 153.
    Crist DM, Peake GT, Stackpole PJ. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol 1986; 13: 513–8PubMedGoogle Scholar
  154. 154.
    Hartgens F, Rietjens G, Keizer H, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). Br J Sports Med 2004; 38(3): 253–9PubMedGoogle Scholar
  155. 155.
    Kiraly CL. Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, on liver enzymes. Int J Sports Med 1988; 9: 249–52PubMedGoogle Scholar
  156. 156.
    Peterson GE, Fahey TD. HDL-C in five elite athletes using anabolic-androgenic steroids. Phys Sportsmed 1984; 12: 120–30Google Scholar
  157. 157.
    Webb OL, Laskarzewski PM, Glueck CJ. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism 1984; 33: 971–5PubMedGoogle Scholar
  158. 158.
    Cohen JC, Faber WM, Benade A, et al. Altered serum lipoprotein profiles in male and female power lifters ingesting anabolic steroids. Phys Sportsmed 1986; 14: 131–6Google Scholar
  159. 159.
    Cohen JC, Noakes TD, Benade A. Hypercholesterolemia in male power lifters using anabolic-androgenic steroids. Phys Sportsmed 1988; 16: 49–56Google Scholar
  160. 160.
    Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. JAMA 1984; 252: 507–13PubMedGoogle Scholar
  161. 161.
    Baldo-Enzi G, Giada F, Zuliani G, et al. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism 1990; 39: 203–8PubMedGoogle Scholar
  162. 162.
    Müller RW, Hollmann W. Akute Lipoproteibeeinflüssung durch ein anaboles Steroid bei Kraftsportlern. Dtsch Z Sportmed 1988; 39: 35–40Google Scholar
  163. 163.
    Glazer G, Suchman AL. Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 1994; 43: 204–10PubMedGoogle Scholar
  164. 164.
    Zmuda JM, Fahrenbach MC, Younkin BT, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 1993; 42: 446–50PubMedGoogle Scholar
  165. 165.
    Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261: 1165–8PubMedGoogle Scholar
  166. 166.
    Kouri EM, Pope JH, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin J Sport Med 1996; 6: 152–7PubMedGoogle Scholar
  167. 167.
    Durstine JL, Haskell WL. Effects of exercise training on plasma lipids and lipoproteins. In: Holloszy JO, editor. Exercise and sport sciences reviews. Baltimore (MD): Williams & Wilkins, 1994: 477–522Google Scholar
  168. 168.
    Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels; a literature review. Arch Intern Med 1991; 151: 1925–33PubMedGoogle Scholar
  169. 169.
    Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med 2002; 32: 285–96PubMedGoogle Scholar
  170. 170.
    Pärssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Med 2002; 32: 83–94PubMedGoogle Scholar
  171. 171.
    Zuliani U, Bernardini B, Catapano A, et al. Effects of anabolic steroids, testosterone, HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 1989; 10: 62–6PubMedGoogle Scholar
  172. 172.
    Hurley BF, Hagberg JM, Seals DR, et al. Hepatic triglyceride lipase modulates high density lipoprotein cholesterol levels in weightlifters and runners [abstract]. Clin Res 1984; 32: 398AGoogle Scholar
  173. 173.
    Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism 1987; 36: 949–52PubMedGoogle Scholar
  174. 174.
    Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87: 136–43PubMedGoogle Scholar
  175. 175.
    Teruel JL, Lasuncion MA, Rivera M, et al. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997 Apr; 29: 569–75PubMedGoogle Scholar
  176. 176.
    Lippi G, Guidi G, Ruzzenente O, et al. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 1997; 57: 507–11PubMedGoogle Scholar
  177. 177.
    Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 1983; 32: 413–20PubMedGoogle Scholar
  178. 178.
    Taggart HM, Applebaum BD, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982; 31: 1147–52PubMedGoogle Scholar
  179. 179.
    Zmuda JM, Thompson PD, Dickenson R, et al. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996; 77: 1245–8Google Scholar
  180. 180.
    Cohen LI, Hartford CG, Rogers GG. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc 1996; 28: 176–9PubMedGoogle Scholar
  181. 181.
    Climstein M, O’Shea P, Zauner C, et al. The effects of anabolic steroids on left ventricular performance of elite powerlifters and endurance athletes [abstract]. Med Sci Sports Exerc 1990; 23: S64Google Scholar
  182. 182.
    De Piccoli B, Giada F, Benettin A, et al. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med 1991; 12: 408–12PubMedGoogle Scholar
  183. 183.
    Dickerman RD, Schaller F, Zachariah NY, et al. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 1997; 7: 90–3PubMedGoogle Scholar
  184. 184.
    McKillop G, Todd IC, Ballantyne D. The effects of body building and anabolic steroids on left ventricular structure and function. J Cardiovasc Technol 1989; 8: 23–9Google Scholar
  185. 185.
    Yeater R, Reed C, Ullrich I, et al. Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, plasma lipids. Br J Sports Med 1996; 30: 11–4PubMedGoogle Scholar
  186. 186.
    Palatini P, Giada F, Garavelli G, et al. Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol 1996; 36: 1132–40PubMedGoogle Scholar
  187. 187.
    Salke RC, Rowland TW, Burke EJ. Left ventricular size and function in body builders using anabolic steroids. Med Sci Sports Exerc 1985; 17: 701–4PubMedGoogle Scholar
  188. 188.
    Spataro A, Caselli G, Pelliccia A, et al. Anabolic steroids do not increase left ventricular mass index in well trained athletes [abstract]. Med Sci Sports Exerc 1992; 24: S29Google Scholar
  189. 189.
    Di Bello V, Giorgi D, Bianchi M, et al. Effects of anabolic-androgenic steroids on weight lifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc 1999; 31(4): 514–21PubMedGoogle Scholar
  190. 190.
    Appell HJ, Heller-Umpfenbach B, Feraudi M, et al. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med 1983; 4: 268–74PubMedGoogle Scholar
  191. 191.
    Behrendt H. Effect of anabolic steroids on rat heart muscle cells: I. intermediate filaments. Cell Tissue Res 1977; 180: 303–15PubMedGoogle Scholar
  192. 192.
    Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone. Cell Tissue Res 1977; 181: 423–6PubMedGoogle Scholar
  193. 193.
    Karhunen MK, Ramo MP, Kettunen R. Anabolic steroids alter the haemodynamic effects of endurance training and deconditioning in rats. Acta Physiol Scand 1988; 133: 297–306PubMedGoogle Scholar
  194. 194.
    Liang MT, Paulson DJ, Kopp SJ, et al. Effects of anabolic steroids and endurance exercise on cardiac performance. Int J Sports Med 1993; 14: 324–9PubMedGoogle Scholar
  195. 195.
    Morano I. Influence of exercise and Dianabol on the degradation rate of myofibrillar proteins of the heart and the three fiber types of skeletal muscle of female guinea pigs. Int J Sports Med 1984; 5: 317–9PubMedGoogle Scholar
  196. 196.
    Pesola MK. Reversibility of the haemodynamic effects of anabolic steroids in rats. Eur J Appl Physiol 1988; 58: 125–31Google Scholar
  197. 197.
    Ramo P. Anabolic steroids alter the haemodynamic responses of the canine left ventricle. Acta Physiol Scand 1987; 130: 209–17PubMedGoogle Scholar
  198. 198.
    Ramo P, Kettunen R, Hirvonen L. The effects of anabolic steroids and endurance training on systolic time intervals in the dog. Acta Physiol Scand 1987; 129: 543–8PubMedGoogle Scholar
  199. 199.
    Ramo P, Kettunen R, Timisjarvi J, et al. Anabolic steroids alter the haemodynamic effects of endurance training on the canine left ventricle. Pflugers Arch 1987; 410: 272–8PubMedGoogle Scholar
  200. 200.
    Takala T, Ramo P, Kiviluoma K, et al. Effects of training and anabolic steroids on collagen synthesis in dog heart. Eur J Appl Physiol Occup Physiol 1991; 62: 1–6PubMedGoogle Scholar
  201. 201.
    Takala TE, Kiviluoma K, Kihlstrom M, et al. Effects of physical training, methandione and their combination on the lysosomal hydrolytic activities in dog heart. Int J Sports Med 1992; 13: 52–5PubMedGoogle Scholar
  202. 202.
    Tingus SJ, Carlsen RC. Effect of continuous infusion of an anabolic steroid on murine skeletal muscle. Med Sci Sports Exerc 1993; 25: 485–94PubMedGoogle Scholar
  203. 203.
    Bronson FH, Matherne CM. Exposure to anabolic-androgenic steroids shortens life span of male mice. Med Sci Sports Exerc 1997; 29: 615–9PubMedGoogle Scholar
  204. 204.
    Gragera R, Saborido A, Molano F, et al. Ultrastructural changes induced by anabolic steroids in liver of trained rats. Histol Histopathol 1993; 8: 449–55PubMedGoogle Scholar
  205. 205.
    Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981; 1: 116–28PubMedGoogle Scholar
  206. 206.
    Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73–9PubMedGoogle Scholar
  207. 207.
    Wright JE. Anabolic steroids and athletics. Exerc Sport Sci Rev 1980; 8: 149–202PubMedGoogle Scholar
  208. 208.
    Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26: 2–4PubMedGoogle Scholar
  209. 209.
    Creagh TM, Rubin A, Evans DJ. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Pathol 1988; 41: 441–3PubMedGoogle Scholar
  210. 210.
    Goldman B. Liver carcinoma in an athlete taking anabolic steroids [letter]. J Am Osteopath Assoc 1985; 85(2): 56PubMedGoogle Scholar
  211. 211.
    Kosaka A, Takahashi H, Yajima Y, et al. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. J Gastroenterol 1996; 31: 450–4PubMedGoogle Scholar
  212. 212.
    Strauss RH, Wright JE, Finerman GAM. Anabolic steroid use and health status among forty-two weight trained male athletes [abstract]. Med Sci Sports Exerc 1982; 14: 119Google Scholar
  213. 213.
    Thomson DP, Pearson DR, Costill DL. Use of anabolic steroids by national level athletes [abstract]. Med Sci Sports Exerc 1981; 13: 111Google Scholar
  214. 214.
    Dickerman RD, Pertusi RM, Zachariah NY, et al. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999; 9: 34–9PubMedGoogle Scholar
  215. 215.
    Bahrke MS. Psychological effects of endogenous testosterone and anabolic-androgenic steroids. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 247–78Google Scholar
  216. 216.
    Archer J. The influence of testosterone and human aggression. Br J Psychol 1991; 82: 1–28PubMedGoogle Scholar
  217. 217.
    Annitto WJ, Layman WA. Anabolic steroids and acute schizophrenic episode. J Clin Psychiatry 1980; 41: 143–4PubMedGoogle Scholar
  218. 218.
    Brower KJ, Blow FC, Eliopulos GA, et al. Anabolic androgenic steroids and suicide [letter]. Am J Psychiatry 1989; 146: 1075PubMedGoogle Scholar
  219. 219.
    Pope HGJ, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988; 145: 487–90PubMedGoogle Scholar
  220. 220.
    Pope HGJ, Katz DL. Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry 1990; 51: 28–31PubMedGoogle Scholar
  221. 221.
    Porcerelli JH, Sandler BA. Narcissism and empathy in steroid users. Am J Psychiatry 1995; 152: 1672–4PubMedGoogle Scholar
  222. 222.
    Wroblewska AM. Androgenic-anabolic steroids and body dysmorphia in young men. J Psychosom Res 1997; 42: 225–34PubMedGoogle Scholar
  223. 223.
    Driessen M, Muessigbrodt H, Dilling H, et al. Child sexual abuse associated with anabolic androgenic steroid use [letter]. Am J Psychiatry 1996; 153: 1369PubMedGoogle Scholar
  224. 224.
    Corrigan B. Anabolic steroids and the mind. Med J Aust 1996 Aug; 165: 222–6PubMedGoogle Scholar
  225. 225.
    Schulte HM, Hall MJ, Boyer M. Domestic violence associated with anabolic steriod abuse [letter]. Am J Psychiatry 1993; 150: 348PubMedGoogle Scholar
  226. 226.
    Lindstrom M, Nilsson AL, Katzman PL, et al. Use of anabolic-androgenic steroids among body builders-frequency and attitudes. J Intern Med 1990; 227: 407–11PubMedGoogle Scholar
  227. 227.
    Bahrke MS, Wright JE, Strauss RH, et al. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am J Sports Med 1992; 20: 717–24PubMedGoogle Scholar
  228. 228.
    Choi PY, Parrott AC, Cowan D. High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Hum Psychopharmacol Clin Exp 1990; 5: 349–56Google Scholar
  229. 229.
    Choi PY, Pope HJ. Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry 1994; 6: 21–5PubMedGoogle Scholar
  230. 230.
    Hannan CJ, Friedl KE, Zold A, et al. Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology 1991; 16: 335–43PubMedGoogle Scholar
  231. 231.
    Kouri EM, Lukas SE, Pope JH, et al. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 1995; 40: 73–9PubMedGoogle Scholar
  232. 232.
    Moss H, Panazak G, Tarter R. Personality, mood, psychiatric symptoms among anabolic steroid users. Am J Addict 1992; 1: 315–24Google Scholar
  233. 233.
    Parrott AC, Choi PY, Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J Sports Med Phys Fitness 1994; 34: 292–8PubMedGoogle Scholar
  234. 234.
    Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes: a case series analysis. Am J Sports Med 1990; 18: 422–8PubMedGoogle Scholar
  235. 235.
    Perry PJ, Yates WR, Andersen KH. Psychiatric symptoms associated with anabolic steroids: a controlled, retrospective study. Ann Clin Psychiatry 1990; 2: 11–7Google Scholar
  236. 236.
    Pope HJ, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51: 375–82PubMedGoogle Scholar
  237. 237.
    Su TP, Pagliaro M, Schmidt PJ, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993; 269: 2760–4PubMedGoogle Scholar
  238. 238.
    Malone DJ, Dimeff RJ, Lombardo JA, et al. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med 1995; 5: 25–31PubMedGoogle Scholar
  239. 239.
    Bahrke MS, Strauss RH. Selected psychological characteristics of female anabolic-androgenic (AAS) users [abstract]. Med Sci Sports Exerc 1992; 24: S136Google Scholar
  240. 240.
    Bond AJ, Choi PYL, Pope HG. Assessment of attentional bias and mood in users and non-users of anabolic-androgenic steriods. Drug Alcohol Depend 1995; 37: 241–5PubMedGoogle Scholar
  241. 241.
    Brower KJ, Eliopulos GA, Blow FC, et al. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weightlifters. Am J Psychiatry 1990; 147: 510–2PubMedGoogle Scholar
  242. 242.
    Burnett KF, Kleiman ME. Psychological characteristics of adolescent steroid users. Adolescence 1994; 29: 81–9PubMedGoogle Scholar
  243. 243.
    Pope Jr HG, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000; 57: 133–40PubMedGoogle Scholar
  244. 244.
    Blouin AG, Goldfield GS. Body image and steroid use in male bodybuilders. Int J Eat Disord 1995; 18: 159–65PubMedGoogle Scholar
  245. 245.
    Pope HJ, Katz DL, Hudson JI. Anorexia nervosa and ‘reverse anorexia’ among 108 male bodybuilders. Compr Psychiatry 1993; 34: 406–9PubMedGoogle Scholar
  246. 246.
    Schwerin MJ, Corcoran KJ, Fisher L, et al. Social physique anxiety, body esteem, social anxiety in bodybuilders and self-reported anabolic steroid users. Addict Behav 1996; 21: 1–8PubMedGoogle Scholar
  247. 247.
    Pope HJ, Gruber AJ, Choi P, et al. Muscle dysmorphia: an underrecognized form of body dysmorphic disorder. Psychosomatics 1997; 38: 548–57PubMedGoogle Scholar
  248. 248.
    Pope HJ, Katz D. The Adonis-complex. Champaign (IL): Human Kinetics, 2000Google Scholar
  249. 249.
    Kashkin KB, Kleber HD. Hooked on hormones: an anabolic steroid addiction hypothesis. JAMA 1989; 262: 3166–70PubMedGoogle Scholar
  250. 250.
    Brower KJ, Blow FC, Young JP, et al. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict 1991; 86: 759–68PubMedGoogle Scholar
  251. 251.
    Midgley SJ, Heather N, Davies JB. Dependence-producing potential of anabolic-androgenic steroids. Addict Res 1999; 7: 539–50Google Scholar
  252. 252.
    Brower KJ. Anabolic steroids: potential for physical and psychological dependance. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 279–304Google Scholar
  253. 253.
    Malarkey WB, Strauss RH, Leizman DJ, et al. Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. Am J Obstet Gynecol 1991; 165: 1385–90PubMedGoogle Scholar
  254. 254.
    Gruber AJ, Pope Jr HG. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom 2000; 69: 19–26PubMedGoogle Scholar
  255. 255.
    Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64: 960–3PubMedGoogle Scholar
  256. 256.
    Woodard TL, Burghen GA, Kitabchi AE, et al. Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. J Clin Endocrinol Metab 1981; 53: 905–8PubMedGoogle Scholar
  257. 257.
    Deyssig R, Weissel M. Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. J Clin Endocrinol Metab 1993; 76: 1069–71PubMedGoogle Scholar
  258. 258.
    Kiraly CL, Alen M, Korvola J, et al. The effect of testosterone and anabolic steroids on the skin surface lipids and the population of Propionibacteria acnes in young postpubertal men. Acta Derm Venereol 1988; 68: 21–6PubMedGoogle Scholar
  259. 259.
    Kiraly CL, Collan Y, Alen M. Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. Am J Dermatopathol 1987; 9: 515–9PubMedGoogle Scholar
  260. 260.
    Scott MD, Scott AM. Effects of anabolic-androgenic steroids on the pilosebaceous unit. Cutis 1992; 50: 113–6PubMedGoogle Scholar
  261. 261.
    Calabrese LH, Kleiner SM, Barna BP, et al. The effects of anabolic steroids and strength training on the human immune response. Med Sci Sports Exerc 1989; 21: 386–92PubMedGoogle Scholar
  262. 262.
    Ferenchick G, Schwartz D, Ball M, et al. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci 1992; 303: 78–82PubMedGoogle Scholar
  263. 263.
    Ferenchick GS, Hirokawa S, Mammen EF, et al. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49: 282–8PubMedGoogle Scholar
  264. 264.
    Pernot C, Hartgens F, Keizer HA, et al. Effects of self-administration of high doses androgenic-anabolic steroids on fibrinolytic activity in non elite bodybuilders. Fibrinolysis 1996; 10Suppl. 2: 53–4Google Scholar
  265. 265.
    Pärssinen M, Karila T, Kovanen V, et al. The effect of supraphysiological doses of anabolic androgenic steroids on collagen metabolism. Int J Sports Med 2000; 21: 406–11PubMedGoogle Scholar
  266. 266.
    Pärssinen M, Kujala U, Vartiainen E, et al. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000; 21: 225–7PubMedGoogle Scholar
  267. 267.
    Tannenbaum SD, Rosler H. Proximal humeral fracture in weight lifter using anabolic steroids [abstract]. Arch Phys Med Rehabil 1989; 70: A–89Google Scholar
  268. 268.
    Kramhoft M, Solgaard S. Spontaneous rupture of the extensor pollicis longus tendon after anabolic steroids. J Hand Surg (Br) 1986; 11: 87Google Scholar
  269. 269.
    Laseter JT, Russell JA. Anabolic steroid-induced tendon pathology: a review of the literature. Med Sci Sports Exerc 1991; 23: 1–3PubMedGoogle Scholar
  270. 270.
    Liow R, Tavares S. Bilateral rupture of the quadriceps tendon associated with anabolic steroids. Br J Sports Med 1995; 29: 77–9PubMedGoogle Scholar
  271. 271.
    Stannard JP, Bucknell AL. Rupture of the triceps tendon associated with steroid injections. Am J Sports Med 1993; 21: 482–5PubMedGoogle Scholar
  272. 272.
    Bolgiano EB. Acute rhabdomyolysis due to body building exercise: report of a case. J Sports Med Phys Fitness 1994; 34: 76–8PubMedGoogle Scholar
  273. 273.
    Hageloch W, Appell HJ, Weicker H. Rhabdomyolyse bei Bodybuilder unter Anabolika-Einnahme. Sportverletz Sportschaden 1988; 2: 122–5PubMedGoogle Scholar
  274. 274.
    Masar PP, Kramer S, Vogt M. Rhabdomyolysis in body building: report of a case and literature review [in German]. Schweiz Rundsch Med Prax 1992; 81(36): 1055–8PubMedGoogle Scholar
  275. 275.
    Collins P, Cotterill JA. Gymnasium acne [letter]. Clin Exp Dermatol 1995; 20: 509PubMedGoogle Scholar
  276. 276.
    Mayerhausen W, Riebel B. Acne fulminans following use of anabolic steroids [in German]. Z Hautkr 1989; 64: 875–6PubMedGoogle Scholar
  277. 277.
    Lane PR, Massey KL, Worobetz LJ, et al. Acute hereditary coproporphyria induced by the androgenic/anabolic steroid methandrostenolone (Dianabol). J Am Acad Dermatol 1994; 30: 308–12PubMedGoogle Scholar
  278. 278.
    Scott MJ, Scott MR, Scott AM. Linear keloids resulting from abuse of anabolic androgenic steroid drugs. Cutis 1994; 53: 41–3PubMedGoogle Scholar
  279. 279.
    Lear JT, English J. Anabolic steroids and psoriasis exacerbation [letter]. Br J Dermatol 1996; 134: 809PubMedGoogle Scholar
  280. 280.
    Wemyss-Holden SA, Hamdy FC, Hastie KJ. Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction: is there a relationship? Br J Urol 1994; 74: 476–8PubMedGoogle Scholar
  281. 281.
    Prat J, Gray GF, Stolley PD, et al. Wilms tumor in an adult associated with androgen abuse. JAMA 1977; 237: 2322–3PubMedGoogle Scholar
  282. 282.
    Bryden AA, Rothwell PJ, O’Reilly PH. Anabolic steroid abuse and renal-cell carcinoma [letter]. Lancet 1995; 346: 1306–7PubMedGoogle Scholar
  283. 283.
    Larkin G. Carcinoma of the prostate [letter]. N Engl J Med 1991; 324: 1892–3Google Scholar
  284. 284.
    Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder [letter]. Lancet 1986; 2(8509): 742PubMedGoogle Scholar
  285. 285.
    Sandblom R, Matsumoto A, Schoene R, et al. Obstructive sleep apnoea by testosterone administration. N Engl J Med 1983; 308: 508–10PubMedGoogle Scholar
  286. 286.
    Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globuline. Endocrinology 1984; 114: 2100–6PubMedGoogle Scholar
  287. 287.
    Toth M, Zakar T. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha-reduced derivates to the androgen receptor and to androgen-binding proteins: a suggested role of 5-alpha-reductive steroid metabolism in the dissociation of ‘myotropic’ and ‘androgenic’ activities of 19-nortestosterone. J Steroid Biochem 1982; 17: 653–60PubMedGoogle Scholar
  288. 288.
    Lombardo JA. Anabolic-androgenic steroids. NIDA Res Monogr 1990; 102: 60–73PubMedGoogle Scholar
  289. 289.
    Chang C, Saltzman A, Yeh S, et al. Androgen receptor: an overview. Crit Rev Eukaryotic Gene Expr 1995; 5: 97–125Google Scholar
  290. 290.
    Mayer M, Rosen F. Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am J Physiol 1975; 229: 1381–6PubMedGoogle Scholar
  291. 291.
    Hickson RC, Czerwinski SM, Falduto MT, et al. Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Med Sci Sports Exerc 1990; 22: 331–40PubMedGoogle Scholar
  292. 292.
    Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264–7PubMedGoogle Scholar
  293. 293.
    Ballal SH, Domoto DT, Polack DC, et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29–33PubMedGoogle Scholar
  294. 294.
    Berns JS, Rudnick MR, Cohen RM. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease [letter]. Am J Kidney Dis 1991; 18: 143PubMedGoogle Scholar
  295. 295.
    Bhasin S, Taylor WE, Singh R, et al. The mechanism of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58(12): M1103–1110PubMedGoogle Scholar
  296. 296.
    Tagarakis CV, Bloch W, Hartmann G, et al. Anabolic steroids impair the exercise-induced growth of the cardiac capillary bed. Int J Sports Med 2000; 21: 412–8PubMedGoogle Scholar
  297. 297.
    Tagarakis CV, Bloch W, Hartmann G, et al. Testosteronepropionate impairs the response of the cardiac capillary bed to exercise. Med Sci Sports Exerc 2000; 32: 946–53PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Surgery, Outpatient Clinic Sports MedicineUniversity Hospital Maastricht, and Sports Medicine Center MaastrichtMaastrichtThe Netherlands
  2. 2.Department of Movement SciencesMaastricht UniversityMaastrichtThe Netherlands

Personalised recommendations